Multicenter Phase 2 Trial of Ramucirumab Plus Irinotecan in Patients with Early Relapsed Gastric Cancer During or After Adjuvant Docetaxel Plus S-1 Therapy: RAMIEL Trial (OGSG1901)

ASTRON (OGSG 2401): A multicenter prospective trial of ferric carboxymaltose for patients with gastrointestinal cancer and iron deficiency anemia undergoing chemotherapy

Tumor Response Predicts Survival Time of Ramucirumab Plus Irinotecan in Advanced Gastric Cancer: An Exploratory Analysis of the Phase III RINDBeRG Trial

Identification of Prognostic Factors and Construction of Prognostic Index for Later-line Treatment in Advanced Gastric Cancer: Sub-analysis from the Phase III RINDBeRG Trial

Prognostic Implications of Neutropenia in Advanced Gastric Cancer: An Exploratory Analysis of the RINDBeRG Trial

Predictive Value of Nivolumab-Free Interval in Ramucirumab Plus Irinotecan Therapy: An Exploratory Analysis of the RINDBeRG Trial

胃癌術後補助化学療法時の栄養介入が予後に与える影響（OGSG1108試験の追加観察研究）

Phase I/II study of neoadjuvant chemoradiotherapy consisting of S-1 and cisplatin for patients with clinically resectable type 4 and large type 3 gastric cancer (OGSG1205)

Randomized Phase III Trial of Ramucirumab Beyond Progression Plus Irinotecan in Patients With Ramucirumab-Refractory Advanced Gastric Cancer: RINDBeRG Trial

Phase II Trial of Capecitabine Plus Bevacizumab for Elderly Patients With Metastatic Colorectal Cancer: OGSG 1102